Back to Search
Start Over
Serum heme oxygenase-1 as a prognostic biomarker in patients with acute exacerbation of interstitial lung disease.
- Source :
-
Scientific reports [Sci Rep] 2023 Dec 19; Vol. 13 (1), pp. 22639. Date of Electronic Publication: 2023 Dec 19. - Publication Year :
- 2023
-
Abstract
- Serum heme oxygenase (HO)-1 level has been reported as a clinically reliable diagnostic biomarker for acute exacerbation of interstitial lung disease (ILD); however, its utility for predicting mortality among these patients is unclear. Serum HO-1 levels of patients newly diagnosed with acute exacerbation of ILD were measured at the time of initiating steroid pulse therapy. The relationship between serum HO-1 and various other serum biomarkers, change in HRCT findings, and disease prognosis at 12 weeks after diagnosis of acute exacerbation was evaluated in 51 patients, of whom 17 (33%) had idiopathic pulmonary fibrosis (IPF). Serum HO-1 was higher in patients with acute exacerbation of IPF than in patients with acute exacerbation of other ILDs. Serum HO-1 levels were higher in patients who died within these 12 weeks than in survivors. Among age, sex, comorbidities, IPF diagnosis, HRCT findings, and blood biomarkers, serum HO-1 was a primary predictor of 12-week mortality. In 41 patients who underwent repeat HRCT, serum HO-1 was higher in patients with honeycomb progression than in those without. Serum HO-1 measurement could be useful for evaluating disease mortality and morbidity of patients with acute exacerbation of ILDs.<br /> (© 2023. The Author(s).)
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 13
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 38114539
- Full Text :
- https://doi.org/10.1038/s41598-023-49342-4